{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Lords&min-AnswerDate=2019-07-10", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?legislature.prefLabel=House+of+Lords&min-AnswerDate=2019-07-10", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Lords&min-AnswerDate=2019-07-10&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&legislature.prefLabel=House+of+Lords&min-AnswerDate=2019-07-10", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Lords&min-AnswerDate=2019-07-10", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Lords&min-AnswerDate=2019-07-10", "items" : [{"_about" : "http://data.parliament.uk/resources/1733458", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1733458/answer", "answerText" : {"_value" : "
In addition to the ongoing efforts to control Mpox clade IIb in the United Kingdom, there is widespread planning underway across the Government, including work by the Department, the UK Health Security Agency, and the National Health Service, to prepare for any potential cases of the high consequence infectious disease clades Ia or Ib of Mpox in the UK, and to help prevent onward transmission should any cases be imported.<\/p>
An established clinical countermeasures programme is a core component of our pandemic preparedness and response capability. These clinical countermeasures include personal protective equipment and hygiene consumables, vaccines, and therapeutics, such as antivirals. The programme, including the balance of antivirals stockpiled, is informed by scientific and clinical assessment of the evidence base and is kept under review, building on lessons learned from previous outbreaks and emerging evidence on efficacy from ongoing clinical trials in epidemic hotspots.<\/p>
The Department has noted the recent PALM007 study. The NHS in England has a duty to make available to patients in England any treatment or product recommended as clinically and cost effective by the National Institute for Health and Care Excellence.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/347", "label" : {"_value" : "Biography information for Baroness Merron"} } , "answeringMemberPrinted" : {"_value" : "Baroness Merron"} , "dateOfAnswer" : {"_value" : "2024-10-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-18T10:57:33.573Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Mpox: Vaccination"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government whether, since the PALM007 study has shown the antiviral ingredient tecovirimat does not always reduce the duration of mpox lesions, a mixed stockpile of antiviral agents for mpox is being considered.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4340", "label" : {"_value" : "Biography information for Lord Cashman"} } , "tablingMemberPrinted" : [{"_value" : "Lord Cashman"} ], "uin" : "HL1489"} , {"_about" : "http://data.parliament.uk/resources/1733459", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1733459/answer", "answerText" : {"_value" : "
The Generation Study screens for over 200 conditions which were selected on a set of four principles. The expression, or penetrance, of 22q11.2 deletion syndrome is incomplete, meaning that some people with the syndrome may have no features of the condition. For this and many other conditions, including other microdeletion and microduplication syndromes, Genomics England has taken a conservative approach when applying the four principles, selecting only those conditions where penetrance is high and where treatment must be initiated very early in essentially all cases. Genomics England will review and add conditions during the course of the programme, and will publicise information about any review.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/347", "label" : {"_value" : "Biography information for Baroness Merron"} } , "answeringMemberPrinted" : {"_value" : "Baroness Merron"} , "dateOfAnswer" : {"_value" : "2024-10-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-18T10:59:16.713Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Genomics: Babies"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government why the Genomics England and NHS England \u2018Generation Study\u2019, offering 100,000 newborns whole genome sequencing after birth to diagnose and support a number of genetic conditions, does not include 22q11.2 deletion syndrome which meets the four requisite principles for inclusion.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4321", "label" : {"_value" : "Biography information for Lord Farmer"} } , "tablingMemberPrinted" : [{"_value" : "Lord Farmer"} ], "uin" : "HL1490"} , {"_about" : "http://data.parliament.uk/resources/1733076", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1733076/answer", "answerText" : {"_value" : "
As part of ongoing considerations, NHS England intends to launch a pilot in the coming months extending the Electronic Prescription Service to specific Detained Estate health services in England. Amendments to the National Health Service (Charges for Drugs and Appliances) Regulations 2015 will be made in the autumn, subject to parliamentary time.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/347", "label" : {"_value" : "Biography information for Baroness Merron"} } , "answeringMemberPrinted" : {"_value" : "Baroness Merron"} , "dateOfAnswer" : {"_value" : "2024-10-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-18T10:55:59.057Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Prescriptions: Prisons"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 8 October (HL957), when they expect considerations on extending the Electronic Prescription Service to conclude, and a decision to be taken.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/452", "label" : {"_value" : "Biography information for Lord Bradley"} } , "tablingMemberPrinted" : [{"_value" : "Lord Bradley"} ], "uin" : "HL1441"} , {"_about" : "http://data.parliament.uk/resources/1733097", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1733097/answer", "answerText" : {"_value" : "
In the latest year [2022-23] of the Family Resources Survey approximately 11% of adults were black or minority ethnic individuals. This sample is large enough to provide income and poverty data breakdowns by ethnicity.<\/p>
<\/p>
The Family Resources Survey sample is drawn by address with stratification of postcode areas by economic standing, such that the achieved sample is representative by economic status. The FRS sample is not drawn by any family characteristic, protected or otherwise, because only the address is known at the point of draw; the address\u2019 occupants are unknown until the later stage of interview. Thus, there is no direct mechanism to alter the issued sample to increase the number of black or minority ethnic families.<\/p>
<\/p>
We already publish accredited official statistics, including poverty data broken down by ethnicity, in the annual Family Resources Survey-based Households below average income (HBAI) statistics - GOV.UK (www.gov.uk)(opens in a new tab)<\/a>.<\/p> <\/p>